Latest Period
Q1 2026
Security Snapshot
TScan Therapeutics, Inc. - Voting Common Stock, $0.0001 par value per share (TCRX) Institutional Ownership
CUSIP: 89854M101
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
59
Shares (Excl. Options)
32,503,875
Price
$1.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Voting Common Stock, $0.0001 par value per share
- Symbol
- TCRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 32,503,875
- Total 13F value
- $32,818,057
- Portfolio coverage rank
- 0%
- Share change
- +1,835,918
- Value change
- +$1,858,329
- Number of holders
- 59
- Shares outstanding
- 55,838,719
- SEC-reported price per share
- $1.22
- Insider filing price
- $1.22
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TCRX - TScan Therapeutics, Inc. - Voting Common Stock, $0.0001 par value per share is tracked under CUSIP 89854M101.
- 59 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 60 to 59 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $30,691,928 to $32,818,057.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 59 institutions filings for Q1 2026.
Security key
89854M101
Latest holder period
Q1 2026
13F holders
59
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
TCRX full holder history
TScan Therapeutics, Inc. SEC filings
TScan Therapeutics, Inc. company facts
TScan Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89854M101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
TCRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 15% | +37% | $11,393,153 | +$3,625,000 | 7,857,347 | +47% | Lynx1 Capital Management LP | 30 Jun 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $5,912,985 | +$333,632 | 5,578,288 | +6% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| K2 HealthVentures Equity Trust LLC | 6.9% | $5,764,320 | 3,602,700 | K2 HealthVentures Equity Trust LLC | 31 Dec 2024 | |||
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.1% | $5,600,000 | 3,500,000 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| Adage Capital Management, L.P. | 2.5% | $1,957,500 | 1,350,000 | Adage Capital Management, L.P. | 30 Jun 2025 | |||
| BlackRock, Inc. | 1.8% | -72% | $1,475,894 | -$2,875,873 | 958,373 | -66% | BlackRock, Inc. | 30 Jun 2025 |
| EcoR1 Capital, LLC | 1.3% | $1,060,533 | 662,833 | EcoR1 Capital, LLC | 31 Mar 2025 |
As of 31 Mar 2026, 59 institutional investors reported holding 32,503,875 shares of TScan Therapeutics, Inc. - Voting Common Stock, $0.0001 par value per share (TCRX). This represents 58% of the company’s total 55,838,719 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
56%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 14% | 8,019,148 | 0% | 1.3% | $8,099,339 |
| BVF INC/IL | 10% | 5,564,290 | +6.5% | 0.18% | $5,619,933 |
| BAKER BROS. ADVISORS LP | 5% | 2,784,792 | 0% | 0.02% | $2,812,640 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 2,154,256 | 0% | 0% | $2,175,799 |
| BlackRock, Inc. | 3.3% | 1,840,952 | -0.42% | 0% | $1,859,362 |
| MILLENNIUM MANAGEMENT LLC | 2.6% | 1,460,285 | +262% | 0% | $1,474,888 |
| RENAISSANCE TECHNOLOGIES LLC | 2.4% | 1,364,783 | +20% | 0% | $1,378,431 |
| Deer Management Co. LLC | 2.2% | 1,245,504 | 0% | 0.2% | $1,257,959 |
| TWO SIGMA INVESTMENTS, LP | 2.2% | 1,209,009 | +86% | 0% | $1,221,099 |
| Aberdeen Group plc | 1.6% | 918,020 | -49% | 0% | $927,200 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.4% | 808,356 | +330% | 0% | $816,440 |
| DC Funds, LP | 1.1% | 630,000 | 0% | 42% | $630,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 616,952 | +9.7% | 0% | $623,340 |
| GSA CAPITAL PARTNERS LLP | 0.68% | 378,960 | +68% | 0.02% | $383,000 |
| D. E. Shaw & Co., Inc. | 0.57% | 319,587 | +360% | 0% | $322,783 |
| CITADEL ADVISORS LLC | 0.57% | 318,411 | +95% | 0% | $321,596 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 305,772 | 0% | 0% | $308,830 |
| MARSHALL WACE, LLP | 0.43% | 237,346 | -30% | 0% | $239,719 |
| STATE STREET CORP | 0.37% | 207,313 | 0% | 0% | $209,386 |
| ACADIAN ASSET MANAGEMENT LLC | 0.36% | 201,987 | +584% | 0% | $201,000 |
| MORGAN STANLEY | 0.31% | 173,643 | -23% | 0% | $175,379 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.28% | 157,228 | -27% | 0% | $158,800 |
| JANE STREET GROUP, LLC | 0.26% | 144,421 | -63% | 0% | $145,865 |
| BROWN BROTHERS HARRIMAN & CO | 0.26% | 143,051 | 0% | 0% | $144,482 |
| Verdad Advisers, LP | 0.24% | 134,001 | 0.15% | $135,341 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q1 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 32,503,875 | $32,818,057 | +$1,858,329 | $1.01 | 59 |
| 2025 Q4 | 30,693,604 | $30,691,928 | -$7,374,797 | $1.00 | 60 |
| 2025 Q3 | 34,601,160 | $62,910,264 | -$1,894,623 | $1.82 | 72 |
| 2025 Q2 | 35,724,879 | $51,820,655 | -$5,881,550 | $1.45 | 79 |
| 2025 Q1 | 40,135,840 | $55,389,702 | -$2,855,488 | $1.38 | 92 |
| 2024 Q4 | 41,522,755 | $126,231,784 | -$5,917,073 | $3.04 | 87 |
| 2024 Q3 | 41,835,445 | $208,343,506 | +$256,552 | $4.98 | 86 |
| 2024 Q2 | 41,438,662 | $242,461,718 | +$40,505,361 | $5.85 | 78 |
| 2024 Q1 | 34,291,369 | $272,339,183 | +$19,079,789 | $7.94 | 65 |
| 2023 Q4 | 31,912,819 | $186,051,742 | +$7,213,515 | $5.83 | 54 |
| 2023 Q3 | 28,588,231 | $73,196,468 | +$2,177,876 | $2.56 | 32 |
| 2023 Q2 | 27,951,619 | $69,879,871 | +$45,817,232 | $2.50 | 28 |
| 2023 Q1 | 9,667,555 | $20,309,551 | +$609,616 | $2.10 | 28 |
| 2022 Q4 | 9,519,305 | $14,788,379 | -$121,391 | $1.55 | 28 |
| 2022 Q3 | 9,508,092 | $29,003,732 | -$530,741 | $3.05 | 24 |
| 2022 Q2 | 9,682,082 | $30,449,817 | +$1,528,632 | $3.14 | 23 |
| 2022 Q1 | 9,407,022 | $26,340,000 | -$1,500,189 | $2.80 | 24 |
| 2021 Q4 | 9,861,945 | $44,380,000 | -$2,457,435 | $4.50 | 28 |
| 2021 Q3 | 9,504,939 | $78,230,000 | +$78,229,998 | $8.34 | 25 |